The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone

Clinical and Experimental Immunology

Volumn 124, Issue 1, 2001, Pages 157-162

  Schmidt, E ^a   Reimer, S ^a   Kruse, N ^a   Brocker E B ^a   Zillikens, D ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Autoantibody; BP180; Cytokine; mRNA

Indexed keywords

ANTIBODY; ANTIGEN BP 180; AUTOANTIGEN; CHEMOATTRACTANT; DAPSONE; IMMUNOGLOBULIN G; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; NICOTINAMIDE; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; BLISTER; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; KERATINOCYTE; NEUTROPHIL CHEMOTAXIS; NEWBORN; PEMPHIGOID; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUTOANTIBODIES; AUTOANTIGENS; CELLS, CULTURED; CHEMOTAXIS, LEUKOCYTE; DAPSONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-6; INTERLEUKIN-8; KERATINOCYTES; NEUTROPHIL INFILTRATION; NIACINAMIDE; PEMPHIGOID, BULLOUS; RABBITS; RNA, MESSENGER;

EID: 0035000916     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2001.01503.x     Document Type: Article

References (31)

1. 1 Zillikens D. Acquired skin disease of hemidesmosomes. J Dermatol Sci 1999; 20:134-54.
2. 2 Schmidt E, Zillikens D. Autoimmune and inherited subepidermal blistering disease: advances in the clinic and the laboratory. Adv Dermatol 2000; 16:113-57.
3. 3 Gammon WR, Merrit CC, Lewis DM, Sams WM, Carlo JR, Wheeler CE Jr An in vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes, and complement. J Invest Dermatol 1982; 78:285-90.
4. 4 Liu Z, Giudice GJ, Swartz SJ, Fairley JA, Till GO, Troy JL, Diaz LA. The role of complement in experimental bullous pemphigoid. J Clin Invest 1995; 95:1539-44.
5. 5 Liu Z, Giudice GJ, Zhou X, Swartz SJ, Troy JL, Fairley JA, Till GO, Diaz LA. . A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest 1997; 100:1256-63.
6. 6 Liu Z, Shipley JM, Thiennu HV, Zhou X, Diaz LA, Werb Z, Senior RM. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J Exp Med 1998; 188:475-82.
7. 7 Liu Z, Shapiro SD, Zhou X, Twining SS, Senior RM, Giudice GJ, Fairley JA, Diaz LA. A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest 2000; 105:113-23.
8. 8 Person JR, Rogers RS III Bullous pemphigoid responding to sulfapyridine and the sulfones. Arch Dermatol 1977; 113:610-5.
9. 9 Venning VA, Millard PR, Wojnarowska F. Dapsone as first line therapy for bullous pemphigoid. Br J Dermatol 1989; 120:83-92.
10. 10 Booth SA, Moody CE, Dahl MV, Herren MJ, Nelson RD. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol 1992; 98:135-40.
11. 11 Harvath L, Yancey KB, Katz SI. Selective inhibition of human neutrophil chemotaxis to N-formyl-methionyl-leucyl-phenylalanine by sulfones. J Immunol 1986; 137:1305-11.
12. 12 Stendahl O, Molin L, Dahlgren C. The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone. J Clin Invest 1978; 62:214-20.
13. 13 Wozel G, Barth J. Current aspects of modes of action of dapsone. Int J Dermatol 1988; 27:547-52.
14. 14 Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report. Arch Dermatol 1986; 122:670-4.
15. 15 Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone S, Mutasim D. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994; 130:753-8.
16. 16 Hornschuh B, Hamm H, Wever S, Hashimoto T, Schröder U, Bröcker E-B, Zillikens D. Treatment of 16 patients with oral tetracycline and niacinamide and topical clobetasol. J Am Acad Dermatol 1997; 36:101-3.
17. 17 Barker JNWN, Jones ML, Mitra RS et al. Modulation of keratinocyte-derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes. Am J Pathol 1991; 139:869-76.
18. 18 Schmidt E, Ambach A, Bastian B, Bröcker EB, Zillikens D. Elevated levels of interleukin-8 in blister fluid of bullous pemphigoid compared with suction blisters of healthy controls. J Am Acad Dermatol 1996; 34:310-2.
19. 19 Liu Z, Zhou M, Fleming G, Giudice G, Diaz LA. Cellular events in experimental bullous pemphigoid: mast cells, but not T or B lymphocytes, natural killer cells, or macrophages, play a major role in the early stage of subepidermal blistering. J Invest Dermatol 1999; 112:556(Abstract).
20. 20 Schmidt E, Reimer S, Kruse N, Jainta S, Bröcker E-B, Marinkovich MP, Giudice GJ, Zillikens D. Autoantibodies to BP180 associated with bullous pemphigoid release IL-6 and IL-8 from cultured human keratinocytes. J Invest Dermatol 2000; 115:842-8.
21. 21 Balding SD, Diaz LA, Giudice GJ. . A recombinant form of the human BP180 ectodomain forms a collagen-like, homotrimeric complex. Biochemistry 1997; 36:8821-30.
22. 22 Zillikens D, Rose PA, Balding SD et al. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol 1997; 109:573-9.
23. 23 Zillikens D, Kawahara Y, Ishiko A, et al. A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. J Invest Dermatol 1996; 106:1333-8.
24. 24 Kruse N, Pette M, Toyka K, Rieckmann P. Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. J Immunol Meth 1997; 210:195-203.
25. 25 Katz SI. Commentary: Sulfoxone (Diasone) in the treatment of dermatitis herpetiformis. Arch Dermatol 1982; 118:809-12.
26. 26 Dahl MV, Falk NJ, Carpenter R, Michael AF. Membrane attack complex of complement in dermatitis herpetiformis. Arch Dermatol 1985; 121:70-2.
27. 27 Thuong-Nguyen V, Kadunce DP, Hendrix JD, Gammon WR, Zone JJ. Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. J Invest Dermatol 1993; 100:349-55.
28. 28 Zuidema J, Hilbers-Modderman ESM, Merkus FWHM. Clinical pharmocokinetics of dapsone. Clin Pharmacokinet 1986; 11:299-310.
29. 29 Petley A, Macklin B, Renwick AG, Wilkin TJ. The pharmacokinetics of nicotinamide in humans and rodents. Diabetes 1995; 44:152-5.
30. 30 Roebuck KA. Regulation of interleukin-8 gene expression. J Interf Cytok Res 1999; 19:429-38.
31. 31 Villarete LH, Remick DG. Transcriptional and post-transcriptional regulation of interleukin-8. Am J Pathol 1996; 149:1685-93.32.